Alzheon
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Speen St Ste 306, Framingham, Massac...Phone Number
(508) 861-7709Website
www.alzheon.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Alzheon
Alzheon is an oral anti-amyloid disease-modifying treatment in Phase 3 testing for Alzheimer's disease. Alzheon was founded in 2013 and is based in Massachusetts, the United States.Explore more
Alzheon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alzheon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Alzheon has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Alzheon launches new products
Check out if Alzheon is spiking on competitors!
Funding: Get notified immidiatlly once Alzheon has new funding data
Alzheon, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alzheon recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alzheon
Click to see if Alzheon had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Alzheon
Compare insights from companies similar to Alzheon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alzheon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alzheon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alzheon.
Alzheon financials insights
Gather financial insights about Alzheon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$7.3M
2015
Series A
$10M
Debt
$6.9M
2016
Debt
$1.3M
2017
Private Equity
$15.8M
2020
Debt
$150K
2022
Series D
$40M
2024
Series E
$100M
Alzheon Tech Stack
A closer look at the technologies used by Alzheon
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Person-Based
Medical Research, Clinical Operations
Alzheon News & Media
Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the publication of two new peer-reviewed scientific papers focused on advancement of understanding of AD and need for new treatments. Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, was invited to presenAlzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it has appointed Muneer A. Satter, JD, MBA to its Board of Directors. "2024 was a transformational year at Alzheon and with the completion of our APOLLOE4 Phase 3 trial and $100M Series E round of funding, we aNew Alzheon Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced a new scientific publication describing its APOLLOE4 Phase 3 study, the first Phase 3 trial focused on AD patients carrying two copies of apolipoprotein ε4 allele (APOE4/4 homozygotes), a population with pressing unmet
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alzheon
Sign Up For FreeTo access detailed company insights
Alzheon is an oral anti-amyloid disease-modifying treatment in Phase 3 testing for Alzheimer's disease. Alzheon was founded in 2013 and is based in Massachusetts, the United States.... Read More
